Abstract

Trypanosoma brucei causes human African trypanosomiasis and Nagana disease in cattle, imposing substantial medical and economic burden in sub-Saharan Africa. The current treatments have limitations, including the requirement for elaborated protocols, development of drug resistance, and they are prone to adverse side effects. In vitro screening of a library of 14 dinuclear-thiolato bridged arene ruthenium complexes, originally developed for treatment of cancer cells, resulted in the identification of 7 compounds with IC50 values ranging from 3 to 26 nM. Complex [(η6-p-MeC6H4Pri)2Ru2(μ2-SC6H4-o-Pri)3]Cl (2) (IC50 = 4 nM) and complex [(η6-p-MeC6H4Pri)2Ru2(μ2-SCH2C6H4-p-But)2(μ2-SC6H4-p-OH)]BF4(9) (IC50 = 26 nM) were chosen for further assessments. Application of complex 2 and 9 at 20 nM and 200 nM, respectively, for 4.5 h induced alterations in the trypanosome mitochondrion as evidenced by immunofluorescence employing an antibody against mitochondrial Hsp70 and Mitotracker labeling. Transmission electron microscopy of parasites taken at 2 and 4h of treatment demonstrated massive alterations in the mitochondrial ultrastructure, while other organelles and structural elements of the parasites remained unaffected. Complex 2 treated trypanosomes exhibited a distorted mitochondrial membrane, and the mitochondrial matrix was transformed into an amorphous mass with different degrees of electron densities. Complex 9 did not notably impair the integrity of the membrane, but the interior of the mitochondrion appeared either completely translucent, or was filled with filamentous structures of unknown nature. Dose- and time-dependent effects of these two compounds on the mitochondrial membrane potential were detected by tetramethylrhodamine ethyl ester assay. Thus, the mitochondrion and associated metabolic processes are an important target of dinuclear thiolato-bridged arene ruthenium complexes in T. brucei.

Highlights

  • Human African trypanosomiasis (HAT), referred to as African sleeping sickness, is induced by infection with the flagellated protozoan parasites Trypanosoma brucei gambiense and T. b. rhodesiense

  • We have previously reported that several mononuclear and dinuclear thiolato-bridged ruthenium complexes exhibit promising in vitro activities against the intracellular apicomplexan parasites Toxoplasma gondii and Neospora caninum (Basto et al, 2017, 2019)

  • We investigated the in vitro activities of a small panel of 14 dinuclear thiolato-bridged arene ruthenium complexes against T. brucei bloodstream forms in culture

Read more

Summary

Introduction

Human African trypanosomiasis (HAT), referred to as African sleeping sickness, is induced by infection with the flagellated protozoan parasites Trypanosoma brucei gambiense and T. b. rhodesiense. Rhodesiense causes a rapidly progressive form of the disease, and is found in Eastern and Southern Africa (Franco et al, 2014). Gambiense is responsible for 98% of all HAT cases, causing chronic infection, and is found in Western and Central Africa, T. b. The drugs in clinical use for the treatment of HAT include pentamidine and suramin for the early and peripheral stage of the disease, and melarsoprol and eflornithine alone or in combination with nifurtimox for the cerebral phase (Büscher et al, 2017). Novel drugs being evaluated in phase II/III clinical trials include oxaborole (SCYX-7158), a benzoxaborole, and the 2-5-nitroimidazole fexinidazole that has recently been approved for human use Veterinary trypanocides to treat Nagana include diminazene aceturate and isometamidium chloride as the two most commonly used drugs (Holmes, 2013)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call